• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

With a big stake in hand, Saman­tha Du files for $115M IPO for Zai Lab

8 years ago
Financing
China

Bris­tol-My­ers shares sink af­ter an­oth­er set­back for its im­muno-on­col­o­gy fran­chise drugs

8 years ago
R&D

As Trump lash­es out at Fra­zier again, J&J's Alex Gorsky says he's not aban­don­ing pres­i­den­t's coun­cil

8 years ago
Pharma

Biosims mak­ing slow progress bat­tling block­busters for mar­ket share; Fi­bro­Gen rais­ing $300M

8 years ago
News Briefing

Drug de­vel­op­ers face in­creas­ing­ly risky tightrope walk be­tween top-line re­sults and hard da­ta

8 years ago
R&D

With an eye on the FDA, Lex­i­con and Sanofi line up more pos­i­tive da­ta on di­a­betes drug

8 years ago
R&D

What's worth $500M-plus? The Big 6 deals of Q2 show you where the mon­ey is — and is­n't

8 years ago
Pharma

Is Ama­zon plan­ning to dis­rupt the $560B pre­scrip­tion drug mar­ket?

8 years ago
Pharma

Trump's re­newed broad­sides on drug pric­ing did­n't even dent bio­phar­ma this time

8 years ago
Bioregnum
Opinion

J&J beefs up neu­ro pipeline, bags a new de­pres­sion drug from Cere­cor in $45M deal

8 years ago
Pharma

Cel-Sci shares jump af­ter FDA lifts hold; New up­start is look­ing for Eu­ro mar­ket­ing pacts with biotech

8 years ago
News Briefing

In a rare mis­fire, Re­gen­eron scraps its RSV drug af­ter a PhI­II fail­ure

8 years ago
R&D

Mer­ck CEO Ken Fra­zier re­signs from Trump coun­cil in protest, and the pres­i­dent swift­ly bites back

8 years ago
Pharma

Zyner­ba shares crushed (again) as back-to-back flops leave lead drug un­der a cloud

8 years ago
R&D

Fo­cused on da­ta and drug de­vel­op­ment, Soft­Bank hunts new $1B biotech deals — re­port

8 years ago
Pharma

Mundiphar­ma picks up a PhI­II-ready chemo cre­ation in $250M deal

8 years ago
Pharma

No­var­tis part­ner Oph­thotech says wet-AMD drug Fo­vista goes 0-for-3 in PhI­II

8 years ago
R&D

No­var­tis vet­er­an David Ep­stein takes lead­er­ship role at Ru­bius

8 years ago
Peer Review

Here's why Su­cam­po paid $200M for its PhI­II Nie­mann-Pick drug

8 years ago
R&D

Pere­grine slash­es R&D in a re­org that claims 60 jobs; Zai Labs in hunt for $150M IPO - re­port

8 years ago
News Briefing

GSK aban­dons Ion­is' FDA-ready in­ot­ersen as new CEO sweeps out rare dis­ease ef­forts

8 years ago
Pharma

Dicer­na es­ca­lates war with Al­ny­lam over RNAi se­crets, claim­ing its ri­val wants a mo­nop­oly

8 years ago
Pharma

Gilead cir­cles Feb­ru­ary 12 on its cal­en­dar as D-day for its HIV fran­chise

8 years ago
Pharma

Gush­ing red ink, biotech bil­lion­aire Soon-Sh­iong slash­es staff at NantHealth by 300, sells as­sets

8 years ago
People
R&D
First page Previous page 1091109210931094109510961097 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times